EyePoint Pharmaceuticals announces first patient dosed in Phase 2 DAVIO 2 clinical trial

According to the company, the clinical trial is reviewing EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).

FDA approves ranibizumab-eqrn as a biosimilar product interchangeable with ranibizumab injection for all five indications

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

Wills Eye Hospital’s medical staff expands with addition of four physicians

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

Akari Therapeutics announces positive results from recent pre-clinical studies

July 28, 2022

Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular degeneration (dAMD), a disease with no approved treatments.